Marshall Financial Group LLC Acquires New Shares in DexCom, Inc. (NASDAQ:DXCM)

Marshall Financial Group LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 13,235 shares of the medical device company’s stock, valued at approximately $1,029,000.

Other large investors have also recently bought and sold shares of the company. Flagship Harbor Advisors LLC bought a new stake in shares of DexCom during the fourth quarter worth about $454,000. Linden Thomas Advisory Services LLC grew its holdings in DexCom by 2.2% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 21,772 shares of the medical device company’s stock worth $1,693,000 after acquiring an additional 473 shares during the last quarter. Dynamic Advisor Solutions LLC increased its position in DexCom by 26.8% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 3,902 shares of the medical device company’s stock valued at $303,000 after acquiring an additional 825 shares during the period. Fifth Third Bancorp raised its stake in shares of DexCom by 21.5% during the fourth quarter. Fifth Third Bancorp now owns 31,347 shares of the medical device company’s stock valued at $2,438,000 after acquiring an additional 5,553 shares during the last quarter. Finally, Gradient Investments LLC raised its stake in shares of DexCom by 30.1% during the fourth quarter. Gradient Investments LLC now owns 254,543 shares of the medical device company’s stock valued at $19,796,000 after acquiring an additional 58,947 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on DXCM shares. Canaccord Genuity Group increased their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Citigroup upped their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

DexCom Price Performance

DXCM stock opened at $88.75 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company’s 50-day moving average is $79.50 and its 200-day moving average is $77.35. The stock has a market capitalization of $34.67 billion, a PE ratio of 53.14, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.